Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination immunosuppressive therapy consisting of mycophenolic acid (often administered as mycophenolate mofetil), tacrolimus, and standard of care medications (typically including corticosteroids). This regimen works through complementary mechanisms to prevent organ rejection in transplant recipients. Mycophenolic acid inhibits inosine monophosphate dehydrogenase (IMPDH), blocking purine synthesis and lymphocyte proliferation, while tacrolimus inhibits calcineurin, preventing T-cell activation and cytokine production. This combination is primarily used in kidney, liver, heart, and lung transplantation, and increasingly for autoimmune conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mycophenolic acid + tacrolimus + standard of care medications.